U.S. Markets close in 53 mins
  • S&P 500

    4,589.57
    +76.53 (+1.70%)
     
  • Dow 30

    34,706.66
    +684.62 (+2.01%)
     
  • Nasdaq

    15,414.12
    +160.07 (+1.05%)
     
  • Russell 2000

    2,204.73
    +57.31 (+2.67%)
     
  • Crude Oil

    67.10
    +1.53 (+2.33%)
     
  • Gold

    1,766.90
    -17.40 (-0.98%)
     
  • Silver

    22.40
    +0.06 (+0.25%)
     
  • EUR/USD

    1.1303
    -0.0019 (-0.1696%)
     
  • 10-Yr Bond

    1.4560
    +0.0220 (+1.53%)
     
  • Vix

    28.24
    -2.88 (-9.25%)
     
  • GBP/USD

    1.3301
    +0.0023 (+0.1756%)
     
  • USD/JPY

    113.1600
    +0.3800 (+0.3369%)
     
  • BTC-USD

    56,696.16
    -555.06 (-0.97%)
     
  • CMC Crypto 200

    1,438.27
    -0.61 (-0.04%)
     
  • FTSE 100

    7,129.21
    -39.47 (-0.55%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

How Gilead's Covid Drug Carried Its Third-Quarter Beat — And Why Shares Fell

·2 min read
How Gilead's Covid Drug Carried Its Third-Quarter Beat — And Why Shares Fell
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A big beat from Gilead's Covid treatment, Veklury, offset mixed sales for its other products. In response, GILD stock toppled Friday.